Pacylex Pharmaceuticals Launches Clinical Trial for Novel AML Cancer Treatment

Pacylex Pharmaceuticals has commenced a critical Phase 1/2 clinical trial for zelenirstat, a promising targeted therapy designed to treat patients with refractory or relapsed Acute Myeloid Leukemia (AML). The trial, led by Dr. Naveen Pemmaraju at The University of Texas MD Anderson Cancer Center, represents a significant advancement in developing innovative cancer treatments.

Zelenirstat, a first-in-class oral small-molecule N-myristoyltransferase inhibitor (NMTi), has demonstrated remarkable potential in preclinical studies. Research published in scientific journals indicates the drug can efficiently kill AML cancer cells, including cancer stem cells, both in laboratory and animal model experiments.

The clinical study builds upon previous Phase 1 research that examined zelenirstat's safety and efficacy in solid tumor and lymphoma patients. Earlier studies involving 29 heavily pre-treated patients revealed promising results, with minimal adverse events and indications of prolonged progression-free and overall survival among patients receiving the recommended dose.

Dr. John Mackey, Chief Medical Officer of Pacylex, highlighted the significance of the trial, noting that preclinical results suggest AML cells are particularly sensitive to zelenirstat. The US Department of Defense is partially supporting the investigation, underscoring the potential importance of this research.

The FDA has already granted zelenirstat both Orphan Drug Designation and Fast Track Designation for AML, signaling regulatory recognition of its innovative approach. Pacylex's broader research portfolio includes 27 additional NMTis with potential applications in antibody drug conjugates for solid tumor treatments.

This clinical trial represents a critical step in developing a targeted therapy that could offer new hope for AML patients who have exhausted conventional treatment options. By focusing on a specific molecular mechanism that enables cancer cell survival, zelenirstat exemplifies the ongoing trend toward precision medicine in oncology.